|Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|Outline of Final Research Achievements
We quantified the HIF-1α protein and ATP in the lungs of mice intraperitoneally or intratracheally treated with LPS. HIF-1α protein significantly increased at early time point (6h after the LPS challenge), and returned to the normal level within 24h in the both models. ATP concentration in lungs were also increased at early time point , however the changes were not statistically significant.
Next, we evaluated the effects of a PHD inhibitor; DMOG on LPS induced lung injury. Intratracheal DMOG treatment significantly increased HIF-1α protein in lungs, and attenuated the increase of alveolar permeability induced by intratracheal LPS administration. However, neutrophilic inflammation was not attenuated by DMOG treatment. It was suggested that the protective effects of DMOG is not mediated by suppression of neutrophilic inflammation.